Home › Blog › Regenexx-SD Orthopedic Stem Cell Injection Results

As a world leader in orthopedic stem cell treatment, we’re one of the few stem cell clinics who publishes entire datasets. What does that mean? Rather than cherry picking only the patients who did the best and ignoring those who didn’t, we think it’s important to publish all of the data which includes the superstar patients and those who didn’t respond. When we have enough data and patients tracked for long enough time periods, we also publish in the peer reviewed medical literature. This is incredibly important for the field of adult stem cell therapy. While we agree that case studies are important and serve a valuable function for patients to be able to identify with other patients in the same predicament, having a doctor quote a guesstimate of success off the top of his head isn’t accurate and doesn’t give patients an honest idea of their chances of recovery.  Here’s our Regenexx-SD outcome data to date (all that we were able to obtain). Almost all patients received a single same day injection of their own bone marrow aspirate derived stem cells (recommended is 2-3 injections, so this is early outcome data) with super platelet mix added.

Patients were asked to respond to a Likert scale question, judging improvement from -100% to +100%. We excluded patients that failed to answer the question and who were not at least 1 month out from treatment and included knee, shoulder, ankle, spine, and hand joints. Most patients were 1-2 months out from their Regenexx-SD treatment.

-The failure to respond rate after one treatment was 37.3%. These are patients who didn’t report at least a +25% improvement. It’s unknown if these patients will respond to a subsequent injection, as recommended is 2-3 injections.

Of the remaining 47 patients:

-The average reported improvement among responders was 60.4 +/- 18% (+/- SD).

-85.1% reported 50% improvement or more

Realize that many of these joint patients (such as the 78.7% that were knee patients) had significant knee arthritis with the majority being total joint replacement candidates.

So a simple question to ask any stem cell clinic where you plan to treat is, “Where’s the data?” Not just the rock star cases who did well or a guess from the doctor about the success rate, but what percentage of patients will fail the treatment? This last question is very important, as any treatment (from stem cells to knee replacement to micro fracture) has a success rate.

Chris Centeno, MD is a specialist in regenerative medicine and the new field of Interventional Orthopedics. Centeno pioneered orthopedic stem cell procedures in 2005 and is responsible for a large amount of the published research on stem cell use for orthopedic applications. View Profile